Brandl Talos has advised Vienna-based biotech company Resonate Bio on its spin-off from the University of Vienna.
According to Brandl Talos, Resonate Bio is pioneering a breakthrough approach in structure-based drug design through its AI-NMR drug discovery platform, which combines artificial intelligence and nuclear magnetic resonance to visualize the movement of dynamic proteins, previously considered “undruggable,” across various therapeutic areas. The platform was developed over several years at the Christian Doppler Laboratory, a collaboration between the University of Vienna and Boehringer Ingelheim.
The Brandl Talos team included Partner Stephan Strass and Associate Daniel Habich.
